Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition

Journal of the National Cancer Institute

Volumn 94, Issue 21, 2002, Pages 1641-1671

  Bonham, Michael J ^a   Galkin, Anna ^b   Montgomery, Bruce ^c   Stahl, William ^c   Agus, David ^b   Nelson, Peter S ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; COMPLEMENTARY DNA; CYTOSKELETON PROTEIN; DIETHYLSTILBESTROL; DOXORUBICIN; MESSENGER RNA; PACLITAXEL; PC SPES; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DNA HYBRIDIZATION; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENETIC CODE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROTUBULE; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DIVISION; DRUGS, CHINESE HERBAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; MICROTUBULES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUBULIN; TUMOR CELLS, CULTURED;

EID: 0037032508     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kubota T, Hisatake J, Hisatake Y, Said JW, Chen SS, Holden S, et al. PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo. Prostate 2000;42:163-71.
2. DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998;339:785-91.
3. Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rosenblatz Z, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000;18:3595-603.
4. Small EJ, Kantoff P, Weinberg VK, Nguyen S, Smith M, Bubley G, et al. A prospective multicenter randomized trial of the herbal supplement, PC-SPES vs. diethylstilbestrol (DES) in patients with advanced, androgen independent prostate cancer (AiPCa) [abstract]. ASCO 2002;709.
5. Hsieh T, Chen SS, Wang X, Wu JM. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Biochem Mol Biol Int 1997;42:535-44.
6. Bonham M, Arnold H, Montgomery B, Nelson PS. Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma. Cancer Res 2002;62:3920-4.
7. Ikezoe T, Chen SS, Heber D, Taguchi H, Koeffler HP. Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate 2001;49:285-92.
8. Wu TS, Shi LS, Kuo SC. Cytotoxicity of Ganoderma lucidum triterpenes. J Nat Prod 2001;64:1121-2.
9. Nagao Y, Ito N, Kohno T, Kuroda H, Fujita E. Antitumor activity of Rabdosia and Teucrium diterpenoids against P 388 lymphocytic leukemia in mice. Chem Pharm Bull (Tokyo) 1982;30:727-9.
10. Sohn J, Lee CH, Chung DJ, Park SH, Kim I, Hwang WI, et al. Effect of petroleum ether extract of Panax ginseng roots on proliferation and cell cycle progression of human renal cell carcinoma cells. Exp Mol Med 1998; 30:47-51.
11. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999;59:4180-4.
12. Hawkins V, Doll D, Bumgarner R, Smith T, Abajian C, Hood L, et al. PEDB: the prostate expression database. Nucleic Acids Res 1999;27: 204-8.
13. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
14. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1989.
15. Verdier-Pinard P, Lai JY, Yoo HD, Yu J, Marquez B, Nagel DG, et al. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol Pharmacol 1998;53:62-76.
16. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56:3042-6.
17. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589-601.
18. Levene H. Robust tests for the equality of variance. In: Contributions to probability and statistics. Olkin I, editor. Palo Alto (CA): Stanford University Press; 1960. p. 278-92.
19. Dunnett CW. A multiple comparisons procedure for comparing several treatments with a control. J Am Stat Assoc 1955;50:1096-121.
20. Pienta KJ, Smith DC. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. Semin Oncol 1997;24(5 Suppl 15):S15-72-S15-77.
21. Vaishampayan U, Parchment RE, Jasti BR, Hussain M. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 1999;54(6A Suppl):22-9.
22. Correia JJ, Lobert S. Physiochemical aspects of tubulin-interacting antimitotic drugs. Curr Pharm Des 2001;7:1213-28.
23. Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001;58(2 Suppl 1):108-13.
24. Zunino F, Capranico G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Des 1990;5:307-17.
25. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
26. Chen CT, Gan Y, Au JL, Wientjes MG. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation. Cancer Res 1998;58:2777-83.
27. Rafi MM, Vastano BC, Zhu N, Ho CT, Ghai G, Rosen RT, et al. Novel polyphenol molecule isolated from licorice root (Glycrrhiza glabra) induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. J Agric Food Chem 2002;50:677-84.
28. Downing KH, Nogales E. Tubulin structure: insights into microtubule properties and functions. Curr Opin Struct Biol 1998;8:795-91.
29. Stearns ME, Tew KD. Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J Cell Sci 1988;89:331-42.
30. Giannakakou P, Villalba L, Li H, Poruchynsky M, Fojo T. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. Int J Cancer 1998;75:57-63.
31. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517-24.
32. Knick VC, Eberwein DJ, Miller CG. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 1995;87:1072-7.
33. Sovak M, Seligson AL, Konas M, Hajduch M, Dolezal M, Machala M, et al. Herbal composition PC-SPES for management of prostate cancer: identification of active principles. J Natl Cancer Inst 2002;94:1275-81.